loading
前日終値:
$104.25
開ける:
$105
24時間の取引高:
1.66M
Relative Volume:
1.09
時価総額:
$5.24B
収益:
$4.06B
当期純損益:
$413.08M
株価収益率:
13.24
EPS:
8.01
ネットキャッシュフロー:
$560.48M
1週間 パフォーマンス:
+6.10%
1か月 パフォーマンス:
-39.40%
6か月 パフォーマンス:
-46.38%
1年 パフォーマンス:
-53.91%
1日の値動き範囲:
Value
$102.65
$106.23
1週間の範囲:
Value
$91.86
$107.67
52週間の値動き範囲:
Value
$91.86
$254.15

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name
名前
Charles River Laboratories International Inc
Name
セクター
Healthcare (1151)
Name
電話
781-222-6000
Name
住所
251 BALLARDVALE ST, WILMINGTON, MA
Name
職員
20,100
Name
Twitter
@criverlabs
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
CRL's Discussions on Twitter

CRL を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Diagnostics & Research icon
CRL
Charles River Laboratories International Inc
106.05 5.24B 4.06B 413.08M 560.48M 8.01
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
427.50 169.62B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
186.83 138.06B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
411.49 32.79B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
102.48 29.99B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
143.91 26.61B 15.41B 1.37B 2.11B 7.50

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-21 ダウングレード Goldman Buy → Neutral
2025-03-04 アップグレード Citigroup Sell → Neutral
2025-03-03 アップグレード Redburn Atlantic Sell → Neutral
2025-01-22 ダウングレード William Blair Outperform → Mkt Perform
2025-01-17 ダウングレード UBS Buy → Neutral
2024-11-18 ダウングレード CLSA Hold → Underperform
2024-11-07 アップグレード CLSA Underperform → Hold
2024-10-23 開始されました CLSA Underperform
2024-10-14 開始されました Redburn Atlantic Sell
2024-10-07 ダウングレード Evercore ISI Outperform → In-line
2024-10-02 ダウングレード BofA Securities Buy → Neutral
2024-10-01 ダウングレード Citigroup Neutral → Sell
2024-08-08 ダウングレード JP Morgan Overweight → Neutral
2024-08-08 ダウングレード Robert W. Baird Outperform → Neutral
2024-06-28 ダウングレード Argus Buy → Hold
2024-06-07 開始されました Mizuho Neutral
2024-06-06 開始されました Goldman Buy
2024-02-15 ダウングレード Guggenheim Buy → Neutral
2023-09-13 開始されました TD Cowen Market Perform
2023-07-10 ダウングレード Citigroup Buy → Neutral
2023-02-23 アップグレード Guggenheim Neutral → Buy
2023-01-12 ダウングレード Jefferies Buy → Hold
2022-09-30 アップグレード Jefferies Hold → Buy
2022-08-25 開始されました Credit Suisse Outperform
2022-08-04 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-05-24 開始されました Guggenheim Neutral
2022-04-25 ダウングレード Jefferies Buy → Hold
2022-04-07 開始されました Stephens Overweight
2022-02-17 繰り返されました BofA Securities Buy
2022-02-17 アップグレード Citigroup Neutral → Buy
2022-02-17 繰り返されました Deutsche Bank Buy
2022-02-17 繰り返されました Morgan Stanley Overweight
2022-02-17 繰り返されました UBS Buy
2021-08-05 再開されました Credit Suisse Neutral
2020-12-16 ダウングレード Citigroup Buy → Neutral
2020-09-10 アップグレード Jefferies Hold → Buy
2020-07-01 アップグレード BofA Securities Neutral → Buy
2020-05-13 アップグレード UBS Neutral → Buy
2020-04-21 ダウングレード Jefferies Buy → Hold
2020-03-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-02 開始されました Deutsche Bank Buy
2020-02-18 アップグレード Wolfe Research Peer Perform → Outperform
2020-01-10 アップグレード Goldman Neutral → Buy
2020-01-08 開始されました Wells Fargo Overweight
2020-01-07 開始されました Citigroup Buy
2019-10-18 ダウングレード BofA/Merrill Buy → Neutral
2019-06-10 開始されました SVB Leerink Outperform
2019-04-30 再開されました Evercore ISI Outperform
2018-12-14 開始されました Deutsche Bank Buy
2018-10-09 開始されました UBS Neutral
2018-08-23 アップグレード Raymond James Mkt Perform → Outperform
2018-07-17 アップグレード RBC Capital Mkts Sector Perform → Outperform
2018-06-15 アップグレード KeyBanc Capital Mkts Sector Weight → Overweight
2018-02-14 アップグレード SunTrust Hold → Buy
すべてを表示

Charles River Laboratories International Inc (CRL) 最新ニュース

pulisher
Apr 18, 2025

According to the Latest Report: Dermatology CRO Market - openPR.com

Apr 18, 2025
pulisher
Apr 17, 2025

Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 - MSN

Apr 17, 2025
pulisher
Apr 17, 2025

20 Mid-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey

Apr 17, 2025
pulisher
Apr 17, 2025

Ecotoxicology Market Detailed in New Research Report By 2032| Charles River Laboratories International - openPR.com

Apr 17, 2025
pulisher
Apr 17, 2025

Baird Adjusts Price Target on Charles River Laboratories International to $118 From $101, Keeps Neutral Rating - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Charles River (CRL) Receives Price Target Boost from Baird Analyst | CRL Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 16, 2025

The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid? - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid? - Benzinga

Apr 16, 2025
pulisher
Apr 15, 2025

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call | CRL Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Charles River Labs Earnings: Key Q1 2025 Results Coming May 7What to Watch - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength? - Yahoo

Apr 15, 2025
pulisher
Apr 15, 2025

Charles River (CRL) Price Target Reduced Amid Challenges in Life Sciences Sector | CRL Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

US Stocks Climb With Strong Performances From Real Estate And Utilities - Finimize

Apr 15, 2025
pulisher
Apr 15, 2025

US Markets Climb As Sectors Shine With Solid Gains - Finimize

Apr 15, 2025
pulisher
Apr 14, 2025

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

TD Cowen Adjusts Charles River Laboratories International's PT to $105 From $179, Keeps Hold Rating - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga

Apr 14, 2025
pulisher
Apr 13, 2025

Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate - MSN

Apr 13, 2025
pulisher
Apr 12, 2025

Charles River Gets Hit By The FDA, Too Early To Bet On A Comeback - Seeking Alpha

Apr 12, 2025
pulisher
Apr 11, 2025

Charles River Faces Significant Regulatory And Macro Pressures (NYSE:CRL) - Seeking Alpha

Apr 11, 2025
pulisher
Apr 11, 2025

Charles River (CRL) Faces Uncertainty with FDA's Shift from Animal Testing | CRL Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Wall Street Rebounds, JPMorgan Jumps On Strong Q1 Earnings: What's Driving Markets Friday? - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Baird Adjusts PT on Charles River Laboratories International to $101 From $155, Keeps Neutral Rating - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $140 From $210 - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Charles River (CRL) Faces Uncertainty with FDA's Shift on Animal Testing | CRL Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

FDA's Shift in Testing Requirements Poses Challenge for Charles River (CRL) | CRL Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Why Charles River Laboratories International, Inc. (CRL) Went Down On Thursday? - Insider Monkey

Apr 11, 2025
pulisher
Apr 11, 2025

Charles River Labs Stock (CRL) Crashes 28% as FDA Signals End of Animal Testing Era - TipRanks

Apr 11, 2025
pulisher
Apr 10, 2025

Charles River: Putting FVE Under Review After FDA Announces Plans to Phase Out Animal Testing - Morningstar

Apr 10, 2025
pulisher
Apr 10, 2025

Charles River Laboratories (CRL) Faces Impact from FDA's Shift A - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Inotiv and Charles River stock tumble as FDA moves away from animal testing - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Apr 10, 2025
pulisher
Apr 10, 2025

Charles River Labs stock tumbles as FDA shifts from animal testing - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

FDA Shifts Away from Animal Testing, Charles River (CRL) Shares Could Be Impacted | CRL Stock News - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

FDA to phase out animal testing requirement, adopt AI methods - Seeking Alpha

Apr 10, 2025
pulisher
Apr 10, 2025

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Barclays Adjusts Price Target for Charles River (CRL) Ahead of Q - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Barclays Sticks to Their Hold Rating for Charles River Labs (CRL) - The Globe and Mail

Apr 10, 2025
pulisher
Apr 09, 2025

ROSEN, LEADING INVESTOR COUNSEL, Encourages Charles River Laboratories International, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionCRL - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

Charles River Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) - Benzinga

Apr 09, 2025
pulisher
Apr 09, 2025

Evercore ISI Adjusts PT on Charles River Laboratories International to $135 From $175, Maintains In Line Rating - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

With new site in hand, Portuguese biotech stakes out Peninsula plans - The Business Journals

Apr 09, 2025
pulisher
Apr 09, 2025

Revenues Working Against Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Following 30% Dive - simplywall.st

Apr 09, 2025
pulisher
Apr 08, 2025

Goldman Sachs Adjusts Charles River Laboratories International PT to $150 From $170, Maintains Neutral Rating - MarketScreener

Apr 08, 2025
pulisher
Apr 07, 2025

Charles River Labs stock hits 52-week low at $132.57 - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Bioburden Testing Market Demand, Growth and Future Scope - openPR.com

Apr 07, 2025
pulisher
Apr 07, 2025

Charles River Labs stock hits 52-week low at $132.57 By Investing.com - Investing.com UK

Apr 07, 2025
pulisher
Apr 07, 2025

Animal Model Market Generated Opportunities, Future Scope 2025-2032 | Charles River Laboratories International - openPR.com

Apr 07, 2025
pulisher
Apr 07, 2025

Cell Banking Outsourcing Market Deep Research 2025-2032 | Charles River Laboratories, Cryo-Cell International Inc - openPR.com

Apr 07, 2025

Charles River Laboratories International Inc (CRL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
diagnostics_research DGX
$163.80
price down icon 0.41%
diagnostics_research LH
$217.12
price down icon 1.56%
diagnostics_research WAT
$321.01
price down icon 0.03%
$148.08
price down icon 1.39%
diagnostics_research MTD
$1,004.96
price down icon 1.15%
diagnostics_research IQV
$143.91
price down icon 3.05%
大文字化:     |  ボリューム (24 時間):